Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Apple Turns 50: From Garage Startup to AI Crossroads 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
CAMBRIDGE, Mass., Oct. 06, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today the grant of an inducement award to the company’s newly appointed Chief Medical Officer, Gerald F. Cox, M.D., Ph.D. The award was approved by Editas’ Board of Directors on October 5, 2016 as an inducement material to Dr. Cox entering into employment with Editas, in accordance with NASDAQ Listing Rule 5635(c)(4).
The inducement grant to Dr. Cox consisted of an option to purchase up to 225,000 shares of common stock. The inducement grant is exercisable at a price of $15.48 per share, equal to the closing price per share of Editas’ common stock as reported by NASDAQ on October 5, 2016. The stock option vests over four years, with 25% of the shares vesting on October 3, 2017, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Cox’s continued service relationship with Editas through the applicable vesting dates.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact: Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
